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Age influence on opioid consumption in 
terminally ill digestive cancer patients
Abstract
The aim of this work was to estimate the influence of the age and gender on the opioids usage in terminally 
ill digestive cancer patients. A retrospective files analysis of the 344 patients who had died in two palliative 
units, divided into three groups (< 60, 60–70, > 70 years old) was performed. Morphine Equivalent Daily 
Dose (MEDD) on admission, within the last 3 days, last 5 days and in the last day of life were compared. 
The number of patients receiving coanalgesics and the number of coanalgesics used per patient were also 
analyzed. The amount of opioids remained stable through the last 5 days. The mean daily MEDD values 
in every time intervals were significantly higher in the youngest group than in older ones. The number of 
coanalgesics used was the highest in the youngest group. Smaller number of patients received coanalgesics 
in the oldest group. Women < 60 years old required a significantly higher MEDD than men in each time 
interval, except of the admission. Study confirms the lower amount of opioids used in the elderly digestive 
terminal cancer patients and also within younger males.
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Introduction
The proportion of people aged 65 years and older 
in Europe is steadily increasing. In 2009, this age group 
represented almost 15% of the whole population. By 
2050, estimates indicate that more than one quarter 
will be aged 65 years and older. The greatest per-
centage increase will be among people aged over 85 
years [1]. This group is more likely to die from other 
diseases than cancer, also some studies have indicated 
age-related differences in symptom prevalence, e.g. 
pain decreased with age [2]. Besides, undertreatment 
and misdiagnosis frequently occur owing to the as-
sumptions made by health care providers that pain 
can be the normal consequence of aging. Divergent 
observation exists according to the amount of anal-
getics used in the elderly. Higher pain prevalence in 
women is consistently observed as well by not well 
understood [3]. The aim of this work was to estimate 
the influence of the age and gender on the opioids 
daily consumption in the terminal digestive cancer 
patients.
Methods
A retrospective observational study assessing opi-
oid consumption in terminally ill digestive tract cancer 
patients was performed. Patients died between 2005 
and 2009 in St. Lazarus Hospice and in Department of 
Pain Treatment and Palliative Care, University Hospital 
in Krakow, Poland were included. All files of patients 
that were hospitalized in that time were searched. 
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These who were admitted for at least 3 days before 
death and received strong opioids were included. 
Patients were divided according to their age into three 
groups: below 60 (< 60), between 60 and 70 (60–70) 
and over 70 (> 70) years old. The primary outcome 
was total dose of opioids used over the course of 24 
hours converted to an equivalent dose of parenteral 
morphine in milligrams (MEDD — Morphine Equiva-
lent Daily Dose), following the standard equianalgesic 
conversion tables [4]. MEDD values on admission and 
on the last full day before death were measured. Mean 
values between groups were compared. Mean MEDD 
for the last 3 days and 5 days of stay for each group 
were calculated and compared. MEDD on admission 
was compared with the last day of hospitalization and 
differences between men and women were analyzed. 
The secondary outcomes were the number of patients 
receiving coanalgesicss and the mean number of 
coanalgesics used.
Statistics
To compare differences between groups analysis 
of variance (ANOVA) was used with the Shaffe post 
hoc test. To compare within group differences paired 
Student t-test was used. To compare number of pa-
tients using coanalgesicss Spearman correlation was 
applied. All statistical calculations were performed 
using STATISTICA software. Statistical significance was 
set at the P < 0,05 level. 
Results
During 5-years period of assessing 2189 patients 
died of cancer, among them 771 of primary digestive 
tract. 344 patients (44,6%) received strong opioids 
and were included in further analysis. In the oldest 
group there were significantly more females and in 
the medium group more males (P < 0,05). The char-
acteristics of assessed group are illustrated in Table 1.
The amount of opioids remained stable through 
the last 5 days. In the youngest group it tend to be 
higher than on admission. The mean daily MEDD 
values in every time interval were significantly higher 
in the youngest group than in both older groups 
(P < 0,05). In the youngest group the difference be-
tween the daily dose in the last and the first day of 
hospitalization was found to be the largest (Fig. 1).
The number of co-analgetics used was the highest 
in the youngest group (mean 3,13) in comparison with 
intermediate group (2,60) and the oldest (2,35). The 
difference between the youngest and the oldest group 
occurred statistically significant (P < 0,05) (Tab. 2).
In the oldest group smaller number of patients 
(43% of all the subjects) received co-analgetics (Spear-
man correlation = -0,21; P < 0,05). 
Women < 60 years old had a significantly higher 
MEDD than men every time interval, except of the 
admission time (P < 0.05) (Fig. 2).
There was no significant difference between men 
and women in older groups. The mean MEDD values 
in the group > 74 years were slightly higher among 
the male patients (NS). 
Discussion
Studies indicate that > 90% of the elderly living 
in the community experienced pain within the past 
month, with 41% reporting discomforting, distressing, 
horrible, or excruciating pain [5]. Musculoskeletal pain 
seems to be the most predominant pain, and inactiv-
ity is the most effective strategy used to lessen pain. 
While many of the patients report that activity make 
their pain better, the consequence of inactivity can 
result in additional problems for the elderly. Surveys 
indicate that pain is experienced by more than two 
thirds of those with advanced disease, in cancer it is 
reported in 35–96% of patients. In our population 
44,6% of patients received strong opioids which 
corresponds to other observations that 25–40% of 
older cancer patients experience daily pain and on 
admission to hospice care more than 50% had severe 
pain [6]. Some studies outline the same level of pain 
in older groups, other point that it decreases with 
age [7]. In practice undertreatment and misdiagno-
sis can frequently occur owing to the assumptions 
made by health care providers that pain is a normal 
consequence of aging [8]. That is probably one of the 
reasons that older patients in daily pain are less likely 
to receive any analgesic agent and also three times 
less frequent received strong opioids [9]. 
Table 1. Included group characteristics
  Under 60 60–74 Above 74
Number of patients (%) 71 (20,7) 125 (36,3) 148 (43,0)
Mean age ± SD (years) 52,8 ± 6,4 67,9 ± 4,2 80,3 ± 4,2
Males (%) 42 (59,1) 84 (62,4)* 72 (48,6)*
Mean hospitalization (days) 16,3 (± 21,0) 15,5 (± 21,1) 19,9 (± 25,9)
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Figure 1. MEDD (mean and standard error) values within the groups
Table 2. Coanalgesics used in three groups of patients
  Under 60 60–74 Above 74
Number of patients received coanalgesics 61 (86%) 109 (87%) 124 (84%)
Mean number of coanalgesics used (± SD) 3,13 (1,99)* 2,60 (1,88) 2,35 (2,08)*
Figure 2. MEDD (mean and standard error) sex difference
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The mean MEDD of 22,1 was observed in our older 
cancer patients. Other studies showed much higher 
amounts of opioids given: 105,5 (± 116,2 SD), with 
an increase that ranged between 82–137 mg, asso-
ciated with the presence of neuropathic pain [10]. In 
our analysis younger patients who were on opioids 
demanded higher doses of opioids and coanalgetics. 
Only one small observation showed that older patient 
can receive more opioids than those under 60 [11]. 
Our results are analogous with the other studies: in 
spite of that overall symptom profiles between the 
older and younger groups are similar, in the last days 
of life, patients aged 80 years and older receive sig-
nificantly less parenteral morphine equivalents [12]. 
Concerns exists if older cancer patients experience 
less effective pain management. In a recent study the 
experience and the management of pain (including 
non-opioids, even OTC medications) in older cancer 
patients was no different from that in younger sub-
jects. Older patients are less likely to receive adequate 
analgesia than younger, even though, in relation of 
pain intensity, studies have found no difference be-
tween them. The problem existing with determine the 
effectiveness of cancer pain management depends on 
selecting an appropriate outcome measure [13]. These 
findings may be related to several factors. Specialist 
palliative and geriatric pharmacotherapy is based 
on a slow titration with detailed adverse symptoms 
monitoring, so the assessed elder group could be 
treated more cautiously. Older patients may be more 
sensitive to the analgetic effects of opioids with higher 
peek effect and lower duration of action secondary 
to decreased elimination. Besides, having higher risk 
of poor opioid absorption may also have increased 
drug toxicity due to impaired analgesic metabolism 
[14]. Lower metabolic reserve often leads to more pain 
distress in older patients during the titration phase. In 
the stable phase, after titration, opioid adverse effects 
do not differ between the age groups suggesting that 
older patients are not more susceptible than younger 
adults [15]. Some authors mention older patients 
stoicism and belief that only intolerable suffering is a 
justified reason for complains [16]. 
The very old appear to have a lower requirements 
for medication. They are at higher risk of gastric and 
renal toxicities, e.g. silent and fatal bleeds. Gener-
al recommendations remain regarding the cautious 
use of non-steroid anti-inflammatory drugs in this 
population. Much safer appears to reach earlier for 
the second and third step of WHO analgetic ladder, 
provided that the titration with cause using short 
acting medication first, titrated to comfort and then 
converting to a long acting medications. A better 
understanding of the needs of this population at the 
end of life will enable adequate service planning and 
improved care.
In our study younger women needed more opioids 
than the men in this group of age. This difference 
decreased with the age and the oldest group was 
homogeneous. Higher pain prevalence (from 1,5 times 
in headache to 4 times in fibromyalgia) in women 
is consistently observed but not well explained and 
understood. This observation can be associated with 
sex differences in basic pain mechanisms (nociceptive 
pathways, opioid system, physiology, perceptual sen-
sitivity) and also gender differences in psychological 
factors (like cognitive or emotional appraisal of pain, 
by pain behaviours or even different social roles). Fe-
males are judged using „virtual human” technology 
by the health care students as having more pain than 
males [17]. Women are more likely to report receiving 
health care for musculoskeletal pain and higher rates 
of long-term opioid use is observed in them. Further 
research is needed to address whether gender-specific 
pain treatment may sometimes be warranted [3]. 
There are some limitations in this study. First, the 
patients had been recruited through palliative care 
wards and this involvement may have resulted in 
some bias. Second, in a retrospective method, we 
have not analyzed pain levels assuming that all pa-
tients were equally sufficiently treated. However also 
in other studies retrospective observation of pain by 
different medical staff using different methods can be 
a source of bias. Finally MEDD equivalents may be the 
confounding factor, especially when oral and subcu-
taneous methods of drug delivery was administered. 
In conclusion, this study confirmed the lower 
amount of opioids used in the elderly digestive cancer 
patients also within younger males.
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